{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rubella/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"783a0842-a9d9-5ecf-aa6d-183b6bd947f8","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field eaea9b78-34c3-4d5a-926e-73c9c1ba107a --><h2>Changes</h2><!-- end field eaea9b78-34c3-4d5a-926e-73c9c1ba107a -->","summary":null,"htmlStringContent":"<!-- begin item 4c421e1b-bac7-4080-95c0-8bf94d539d73 --><!-- begin field 0f5056c5-b988-4494-892e-2346eb40c121 --><p><strong>November 2018 </strong>— reviewed. A literature search was conducted in October 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to recommendations have been made.</p><!-- end field 0f5056c5-b988-4494-892e-2346eb40c121 --><!-- end item 4c421e1b-bac7-4080-95c0-8bf94d539d73 -->","topic":{"id":"f4a4135e-ffdc-5df5-b074-abfbec05f014","topicId":"300947fe-8e33-4d94-bbba-f4d16a0ba0f4","topicName":"Rubella","slug":"rubella","lastRevised":"Last revised in November 2018","chapters":[{"id":"3aff984b-cc64-5eef-a912-f7704fcdd2e0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"48701a5d-fb3c-54ae-8a4d-d8ffb0b3fd08","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9fe254c0-d336-5473-8be6-d3b58967643f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"783a0842-a9d9-5ecf-aa6d-183b6bd947f8","slug":"changes","fullItemName":"Changes"},{"id":"0b45633f-1453-5f54-bd26-a5d793bb79e0","slug":"update","fullItemName":"Update"}]},{"id":"4e272831-90b9-5f58-8133-46358fd68bc3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"71613e96-82dc-56c0-a022-916278e5d473","slug":"goals","fullItemName":"Goals"},{"id":"1b880ef4-fa9c-5899-a396-74128fb2bf51","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bebe0c0e-b00e-5e4f-a9f0-bf76dc254163","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"98a30d33-4581-55fa-93c7-c24d96973f5b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a3a2016b-1d86-5856-be17-747a8db43be0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"6d487784-2b75-58e2-acd3-8542a361a149","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0918936-370c-5c73-89bd-9f683169c2b7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"491f6f98-9648-5cc7-9db1-1e8547d3dc07","slug":"definition","fullItemName":"Definition"},{"id":"a56a3c8f-7763-5bac-b0c1-b0f8511b1c11","slug":"cause","fullItemName":"Cause"},{"id":"ec058aad-7d08-52ae-9477-590932a58a90","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0e581233-5a46-5f2e-9b25-a488f499812d","slug":"complications","fullItemName":"Complications"},{"id":"17cdeb34-85ba-5fcb-9f0d-d74a2a51bb20","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"34f907f8-e8f5-5d22-98eb-deba682bb047","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"da084fad-aad1-57b0-8b1f-779333543cf7","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"9198e681-3b01-56a1-883b-f3798a6121b9","slug":"assessment","fullItemName":"Assessment"},{"id":"f9b81df6-547e-5760-9691-a9637efd7f52","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"349017cb-aa09-5c4f-9adb-c3cd0b689c57","fullItemName":"Management","slug":"management","subChapters":[{"id":"dff6856b-8ce5-59b8-911b-139c6149a61e","slug":"non-pregnant-suspected-rubella-or-possible-exposure","fullItemName":"Scenario: Non-pregnant - suspected rubella or possible exposure"},{"id":"ebcad003-eb41-5e51-b604-e5546e36c692","slug":"pregnant-suspected-confirmed-rubella-or-possible-exposure","fullItemName":"Scenario: Pregnant - suspected/confirmed rubella or possible exposure"}]},{"id":"3875c788-962e-5c7a-8996-f7f23d3d842d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"998db942-1480-55a2-b4c9-1e6857da624a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f2be8bd9-0794-52a8-a9f6-0dfa3d744111","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"670c60c7-d470-5310-9dfd-cd849cdb432d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a7436ace-aca6-5c90-9e7c-7b7a5f055024","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"741cd2cb-5dcf-5f25-bae1-8b35a0aa88ba","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b9d37643-879f-5874-a2e5-2eeda488084d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5e833736-5cb6-56ed-ac76-3dedea764334","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9fe254c0-d336-5473-8be6-d3b58967643f","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"b0dc8696-57df-526d-906d-9323ff90d6f5","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 0a9befbf-64a5-45ce-a494-52b46c3c5504 --><h3>Previous changes</h3><!-- end field 0a9befbf-64a5-45ce-a494-52b46c3c5504 -->","summary":null,"htmlStringContent":"<!-- begin item 15a0e352-e89a-4e0f-aaef-c63ac970fac7 --><!-- begin field 3f4bef25-d4f1-43a1-9199-386ad07b391a --><p><strong>July 2015</strong> — minor update. Ibuprofen has been removed as a treatment option for symptomatic relief of rubella infection, due to the lack of safety data for its use in early pregnancy.</p><p><strong>July 2013 </strong>— reviewed. A literature search was conducted in July 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. No major changes to recommendations have been made.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>July 2011</strong> — minor update. More precise paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency. Prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>August 2010</strong> — minor update. Children (and adults) are now advised to stay away from school or work for 6 days after the onset of the rash. Issued in August 2010.</p><p><strong>March 2010 </strong>— minor update. Advice for people with suspected rubella to avoid contact with pregnant women corrected. Issued in March 2010.</p><p><strong>August to December 2009</strong> — this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 3f4bef25-d4f1-43a1-9199-386ad07b391a --><!-- end item 15a0e352-e89a-4e0f-aaef-c63ac970fac7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}